Effect of aripiperazole on psychiatric symptoms in patients with Parkinson disease
Not Applicable
- Conditions
- Parkinson's disease
- Registration Number
- JPRN-UMIN000007711
- Lead Sponsor
- Parkinson Study Group Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients accompanied by serious physical condition or disturbed central nervous system functioning which can cause psychosis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method BPRS, adverse effect
- Secondary Outcome Measures
Name Time Method PDRS, CI-I, CGI-S,MMSE,FAB
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie aripiprazole's efficacy in Parkinson's disease psychosis?
How does aripiprazole compare to typical antipsychotics in managing PD psychosis without motor worsening?
Which biomarkers predict response to dopamine D2 receptor antagonism in JPRN-UMIN000007711 PD patients?
What are the adverse event profiles of aripiprazole in Parkinson's disease trials and management strategies?
How do atypical antipsychotics like aripiprazole and clozapine differ in treating PD-related hallucinations?